Center for Observational and Real World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.
Adelphi Values PROVE, Cheshire, UK.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2055422. doi: 10.1080/21645515.2022.2055422. Epub 2022 May 10.
To reduce morbidity and mortality associated with vaccine-preventable diseases (VPD), it is imperative that vaccination programs are implemented and prioritized throughout all stages of life across all populations. This study aimed to determine vaccine uptake and barriers to vaccination against VPDs among at-risk adult populations in the United States. We conducted a systematic literature review for articles published between January 2010 and June 2020 and identified 153 publications. The review identified 17 at-risk populations. Vaccine uptake was suboptimal among many populations, with factors including age, gender, and disease severity, associated with uptake. This review identified several barriers that impact vaccine uptake among at-risk populations, with concerns over safety, vaccine costs, lack of insurance, and lack of provider recommendation commonly reported across populations. Embracing a national life-course immunization framework that integrates developing policies, guidelines, and education would be a step to addressing these barriers.
为了降低与疫苗可预防疾病(VPD)相关的发病率和死亡率,至关重要的是,在所有人群的所有生命阶段都要实施和优先考虑疫苗接种计划。本研究旨在确定美国高危成年人群中 VPD 疫苗接种的接种率和障碍。我们对 2010 年 1 月至 2020 年 6 月期间发表的文章进行了系统的文献回顾,共确定了 153 篇出版物。该综述确定了 17 个高危人群。许多人群的疫苗接种率不理想,包括年龄、性别和疾病严重程度等因素都与接种率有关。本综述确定了影响高危人群疫苗接种的几个障碍,包括对安全性、疫苗成本、缺乏保险和缺乏提供者建议的担忧,这些问题在各个人群中普遍存在。采用国家生命全程免疫框架,制定政策、指南和教育,将是解决这些障碍的一步。